Nerlynx (neratinib) — United Healthcare

Initial criteria

• Diagnosis of recurrent or metastatic cervical cancer AND Disease is HER2-positive AND Used as second-line or subsequent therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Nerlynx therapy

Approval duration

12 months